These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 22442924)

  • 21. Projected national impact of colorectal cancer screening on clinical and economic outcomes and health services demand.
    Ladabaum U; Song K
    Gastroenterology; 2005 Oct; 129(4):1151-62. PubMed ID: 16230069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Can colorectal cancer mass-screening organization be evidence-based? Lessons from failures: the experimental and pilot phases of the Lazio program.
    Federici A; Barca A; Baiocchi D; Quadrino F; Valle S; Borgia P; Guasticchi G; Giorgi Rossi P;
    BMC Public Health; 2008 Sep; 8():318. PubMed ID: 18803810
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Chemical or immunological tests for the detection of fecal occult blood in colorectal cancer screening?].
    Quintero E
    Gastroenterol Hepatol; 2009 Oct; 32(8):565-76. PubMed ID: 19577340
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nonmedical costs of colorectal cancer screening with the fecal occult blood test and colonoscopy.
    Heitman SJ; Au F; Manns BJ; McGregor SE; Hilsden RJ
    Clin Gastroenterol Hepatol; 2008 Aug; 6(8):912-917.e1. PubMed ID: 18534918
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Screening of high-risk group with colorectal cancer].
    Xu AG; Yu ZJ; Zhong XH; Gan AH; Liu JH; Luo QY
    Zhonghua Yi Xue Za Zhi; 2010 Jan; 90(2):116-8. PubMed ID: 20356496
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is the type of Medicare insurance associated with colorectal cancer screening prevalence and selection of screening strategy?
    Schneider EC; Rosenthal M; Gatsonis CG; Zheng J; Epstein AM
    Med Care; 2008 Sep; 46(9 Suppl 1):S84-90. PubMed ID: 18725838
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness and economic impact of screening for colorectal cancer by mass fecal occult blood testing.
    Helm JF; Russo MW; Biddle AK; Simpson KN; Ransohoff DF; Sandler RS
    Am J Gastroenterol; 2000 Nov; 95(11):3250-8. PubMed ID: 11095350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Taishotoyama Symposium Barriers to colorectal cancer screening: economics, capacity and adherence.
    Inadomi JM
    J Gastroenterol Hepatol; 2008 Dec; 23 Suppl 2():S198-204. PubMed ID: 19120898
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survey of the opinions, knowledge, and practices of gastroenterologists regarding colorectal cancer screening and use of the fecal occult blood test.
    Sharma VK; Corder FA; Fancher J; Howden CW
    Am J Gastroenterol; 2000 Dec; 95(12):3629-32. PubMed ID: 11151904
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Comparison of three FOBT protocols for colorectal cancer screening in Chinese--a multicenter study].
    Li SR; Wang HH; Hu JC; Li N; Liu YL; Wu ZT; Zheng Y; Wang HH; Wu K; Ye H
    Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(10):697-700. PubMed ID: 15932737
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of promoting colorectal cancer screening on screening utilisation: evaluation of the German Campaign "Aktiv gegen Darmkrebs" (Action against Colorectal Cancer).
    Loss J; Eichhorn C; Nagel E
    Z Gastroenterol; 2006 Nov; 44(11):1127-34. PubMed ID: 17115353
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effectiveness of the FLU-FOBT program in primary care a randomized trial.
    Potter MB; Walsh JM; Yu TM; Gildengorin G; Green LW; McPhee SJ
    Am J Prev Med; 2011 Jul; 41(1):9-16. PubMed ID: 21665058
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Faecal occult blood test-based screening programme with high compliance for colonoscopy has a strong clinical impact on colorectal cancer.
    Parente F; Marino B; DeVecchi N; Moretti R; ; Ucci G; Tricomi P; Armellino A; Redaelli L; Bargiggia S; Cristofori E; Masala E; Tortorella F; Gattinoni A; Odinolfi F; Pirola ME
    Br J Surg; 2009 May; 96(5):533-40. PubMed ID: 19358181
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adding familial risk assessment to faecal occult blood test can increase the effectiveness of population-based colorectal cancer screening.
    Dekker N; van Rossum LG; Van Vugt-van Pinxteren M; van Stiphout SH; Hermens RP; van Zelst-Stams WA; van Oijen MG; Laheij RJ; Jansen JB; Hoogerbrugge N
    Eur J Cancer; 2011 Jul; 47(10):1571-7. PubMed ID: 21367600
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of a selective screening for colorectal carcinoma: the Taiwan Multicenter Cancer Screening (TAMCAS) project.
    Chen TH; Yen MF; Lai MS; Koong SL; Wang CY; Wong JM; Prevost TC; Duffy SW
    Cancer; 1999 Oct; 86(7):1116-28. PubMed ID: 10506694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Screening for colorectal cancer.
    Saliangas K
    Tech Coloproctol; 2004 Nov; 8 Suppl 1():s10-3. PubMed ID: 15655587
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness analysis for determining optimal cut-off of immunochemical faecal occult blood test for population-based colorectal cancer screening (KCIS 16).
    Chen LS; Liao CS; Chang SH; Lai HC; Chen TH
    J Med Screen; 2007; 14(4):191-9. PubMed ID: 18078564
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Many participants in fecal occult blood test population screening have a higher-than-average risk for colorectal cancer.
    Worthley DL; Smith A; Bampton PA; Cole SR; Young GP
    Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1079-83. PubMed ID: 16957514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Economic evaluation of colorectal cancer screening with fecal occult blood detection.
    Tárraga López PJ; Marín Nieto E; Celada Rodríguez A; García Molinero MJ; García Olmo D; Solera Albero J
    Rev Esp Enferm Dig; 2000 May; 92(5):334-48. PubMed ID: 10927933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Repeated screening for colorectal cancer with fecal occult blood test in Catalonia, Spain.
    Garcia M; Borràs JM; Binefa G; Milà N; Espinàs JA; Moreno V
    Eur J Cancer Prev; 2012 Jan; 21(1):42-5. PubMed ID: 21849903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.